A proposal attracting attention on Congress.gov would change parts of the federal framework governing compounded medications.
H.R. 6509, the Safeguarding Americans from Fraudulent and Experimental Drugs Act of 2025, or SAFE Drugs Act, was introduced by Rep. Rudy Yakym and Rep. André Carson on December 9, 2025. The official record reviewed for this article lists its referral to the House Energy and Commerce Committee.
The introduced House bill has not become law. Its provisions should not be treated as requirements already in effect.
What compounded medications are
Compounding generally involves combining, mixing, or altering ingredients to meet an individual patient’s needs.
For example, a patient may need medication without a particular dye or in a liquid form instead of a tablet.
The FDA says compounded drugs can meet important medical needs, but they are not FDA-approved. The agency does not review their safety, effectiveness, or quality before they are marketed. They are also different from FDA-approved generic drugs.
What the House bill would change
The introduced text addresses several areas:
Copies of commercially available drugs. It would define an “essentially a copy” test using active ingredients and whether a prescriber determines that a patient-specific change produces a significant difference. It would limit products meeting that definition to no more than 20 compounding instances per month.
Interstate reporting. Certain compounders exceeding a specified monthly threshold for out-of-state patients would report product types and monthly volumes. An exclusion covers specified hospital-pharmacy activity.
Outsourcing-facility inspections. Facilities meeting the bill’s definition of “large-scale” would face an inspection before first compounding and reinspection at least every two years.
Fees. The bill would replace a stated base fee with an amount the Health and Human Services Secretary determines to support safety activities.
The outsourcing-facility amendments would apply six months after enactment. These are provisions of the introduced text; later versions could differ.
Existing oversight already applies
Federal law currently distinguishes between compounding under Section 503A and outsourcing facilities under Section 503B.
Section 503A generally covers qualifying compounding by licensed pharmacists in state-licensed pharmacies or federal facilities, and by licensed physicians. Section 503B covers registered outsourcing facilities.
These categories have different conditions, including prescription requirements, manufacturing practices, reporting, and restrictions on copies of available drugs.
Why the version matters
A separate Senate SAFE Drugs Act of 2026 advanced through the Senate HELP Committee in July. Its sponsor describes labeling and adverse-event reporting provisions.
Readers should not assume every provision associated with the SAFE Drugs name appears in H.R.6509. The bill number, chamber, and version identify the proposal being discussed. Committee advancement also does not establish enactment.
What businesses and patients should watch
For pharmacies and healthcare providers, the practical questions include whether a proposal changes product eligibility, documentation, reporting, inspection schedules, or operating costs.
For patients, a legislative headline alone does not establish that a medication has been banned or that access has changed. Questions about a particular compounded prescription belong with the prescribing clinician and dispensing pharmacist.
RAA will distinguish future legislative action from the requirements already governing these products.
Sources: H.R.6509 official record; introduced House bill text; FDA compounding questions and answers.